- Home
- ASPI
ASPI
ASP Isotopes Inc.
as 07-26-2024 4:00pm EST
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 158.4M | IPO Year: | 2022 |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $5.67 | Next Earning Date: | 08-12-2024 |
| Revenue: | $1,273,380 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2655.95% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ASP Isotopes Inc. (ASPI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AK Jensen Investment Management Ltd | ASPI | 10% Owner | Jul 8 '24 | Buy | $3.40 | 61,849 | $210,230.94 | 6,678,723 | SEC Form 4 |
| AK Jensen Investment Management Ltd | ASPI | 10% Owner | Jul 8 '24 | Buy | $3.05 | 30,000 | $91,497.00 | 6,616,874 | SEC Form 4 |
| AK Jensen Investment Management Ltd | ASPI | 10% Owner | Jul 8 '24 | Buy | $3.05 | 70,000 | $213,360.00 | 6,586,874 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 29 '24 | Buy | $3.20 | 4,313 | $13,801.60 | 555,868 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 29 '24 | Buy | $3.72 | 3,734 | $13,890.48 | 559,602 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 29 '24 | Buy | $3.36 | 5,000 | $16,800.00 | 564,602 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 29 '24 | Buy | $3.34 | 7,500 | $25,050.00 | 572,102 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 26 '24 | Buy | $3.48 | 5,000 | $17,400.00 | 551,555 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 25 '24 | Buy | $3.40 | 5,000 | $17,000.00 | 542,055 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 25 '24 | Buy | $3.46 | 2,500 | $8,650.00 | 544,555 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Apr 25 '24 | Buy | $3.40 | 2,000 | $6,800.00 | 546,555 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Jan 14 '24 | Buy | $1.92 | 2,550 | $4,896.00 | 521,259 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Jan 14 '24 | Buy | $1.91 | 100 | $191.00 | 521,359 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Jan 14 '24 | Buy | $2.54 | 100 | $254.00 | 521,459 | SEC Form 4 |
| Ryan Robert John Andrew | ASPI | Director | Jan 14 '24 | Buy | $2.35 | 15,596 | $36,650.60 | 537,055 | SEC Form 4 |
Latest ASP Isotopes Inc. News
ASPI Breaking Stock News: Dive into ASPI Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now
MT Newswires
11 days ago
ASP Isotopes Raises $34.5 Million From Underwritten Public Share Offering
GlobeNewswire
11 days ago
ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
MT Newswires
14 days ago
ASP Isotopes Prices $30 Million Public Stock Offering; Shares Fall Pre-Bell
GlobeNewswire
14 days ago
ASP Isotopes Announces Pricing of Public Offering of Common Stock
MT Newswires
15 days ago
Top Premarket Decliners
MT Newswires
15 days ago
ASP Isotopes Starts Public Stock Offering; Shares Fall After Hours
GlobeNewswire
15 days ago
ASP Isotopes Announces Proposed Public Offering of Common Stock
Compare ASPI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASPI ASP Isotopes Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.